The Houston Michael E. DeBakey VA Medical Center is the first VA in the country to treat a patient with remedē, a first of its kind treatment for adult patients with central sleep apnea
The Houston Michael E. DeBakey VA Medical Center is the first VA in the country to treat a patient with remedē, a first of its kind treatment for adult patients with central sleep apnea
Respicardia Also Initiates 500-Patient Prospective, Global, Single-Arm Longitudinal Study
Respicardia, Inc., the manufacturer of the only FDA-approved active implantable device for the treatment of central sleep apnea (CSA), today announced the publication of the 24- and 36-month data from the remedē® System Pivotal Trial in the peer-reviewed journal SLEEP….
Pass-through Payment to Provide Additional Medicare Reimbursement for the remedē System
Respicardia, Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has approved an outpatient Transitional Pass-through Payment for the remedē® System, an implantable device that uses…
Add-on Payment to Provide Additional Medicare Reimbursement for the remedē System
Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a New Technology Add-On Payment…
Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch
Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first U.S. commercial case using the remedē® System to treat central sleep apnea …
Company announces strategic relationship with ZOLL Medical
Respicardia, Inc., a private medical technology company, announced today that the company has closed a $58.5 million financing, led by ZOLL Medical Corporation, a leading manufacturer of medical devices and related software solutions. All of Respicardia’s existing major investors helped to complete the financing round …
Breakthrough Treatment of Moderate to Severe Central Sleep Apnea in Adult Patients Now Available
Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its remedē® System, a transvenous implantable neurostimulation system that stimulates the phrenic nerve, and engages the diaphragm to restore natural breathing during sleep in patients with central sleep apnea …
Find media assets, tools and templates:
For media inquiries please contact +1-952-540-4470
The remedē® System is indicated for moderate to severe Central Sleep Apnea in adult patients.
Your doctor will need to evaluate your condition to determine if the remedē system is right for you. You will not be able to have an MRI or diathermy (special heat therapies) if you have the remedē system implanted. The remedē system may be used if you have another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting.
As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection.
Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The remedē system may not work for everyone. There are additional risks associated with removing your system. If you and your doctor decide to remove the system, another surgery will be required.
Be sure to talk with your doctor so that you thoroughly understand all of the risks and benefits associated with the implantation of the remedē system. Rx only. For further information, please call +1-952-540-4470 or email info@respicardia.com.